These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
477 related items for PubMed ID: 9515759
1. Azathioprine: state of the art in inflammatory bowel disease. Sandborn WJ. Scand J Gastroenterol Suppl; 1998; 225():92-9. PubMed ID: 9515759 [Abstract] [Full Text] [Related]
2. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Prefontaine E, Macdonald JK, Sutherland LR. Cochrane Database Syst Rev; 2009 Oct 07; (4):CD000545. PubMed ID: 19821270 [Abstract] [Full Text] [Related]
3. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Prefontaine E, Macdonald JK, Sutherland LR. Cochrane Database Syst Rev; 2010 Jun 16; (6):CD000545. PubMed ID: 20556747 [Abstract] [Full Text] [Related]
4. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Lamers CB, Griffioen G, van Hogezand RA, Veenendaal RA. Scand J Gastroenterol Suppl; 1999 Jun 16; 230():111-5. PubMed ID: 10499471 [Abstract] [Full Text] [Related]
5. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine. Chatzinasiou F, Polymeros D, Panagiotou M, Theodoropoulos K, Rigopoulos D. Acta Dermatovenerol Croat; 2016 Apr 16; 24(1):83-5. PubMed ID: 27149138 [Abstract] [Full Text] [Related]
6. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Cochrane Database Syst Rev; 2009 Jan 21; (1):CD000067. PubMed ID: 19160175 [Abstract] [Full Text] [Related]
7. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Egan LJ, Sandborn WJ, Tremaine WJ. Am J Gastroenterol; 1998 Mar 21; 93(3):442-8. PubMed ID: 9517654 [Abstract] [Full Text] [Related]
8. Methotrexate for induction of remission in refractory Crohn's disease. McDonald JW, Tsoulis DJ, Macdonald JK, Feagan BG. Cochrane Database Syst Rev; 2012 Dec 12; 12():CD003459. PubMed ID: 23235598 [Abstract] [Full Text] [Related]
9. Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits? Su CG, Stein RB, Lewis JD, Lichtenstein GR. Dig Liver Dis; 2000 Dec 12; 32(6):518-31. PubMed ID: 11057928 [Abstract] [Full Text] [Related]
10. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M. Dig Liver Dis; 2005 Jun 12; 37(6):407-17. PubMed ID: 15893279 [Abstract] [Full Text] [Related]
11. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Belaiche J, Desager JP, Horsmans Y, Louis E. Scand J Gastroenterol; 2001 Jan 12; 36(1):71-6. PubMed ID: 11218242 [Abstract] [Full Text] [Related]
12. [Azathioprine treatment of Crohn disease]. Thomsen MK, Vilien M, Gerner CU. Ugeskr Laeger; 2000 Jan 17; 162(3):323-6. PubMed ID: 10680466 [Abstract] [Full Text] [Related]
13. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P, Makrauer F, Reddy S, Burakoff R, Friedman S. Inflamm Bowel Dis; 2006 Apr 17; 12(4):251-7. PubMed ID: 16633046 [Abstract] [Full Text] [Related]
14. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Kim PS, Zlatanic J, Korelitz BI, Gleim GW. Am J Gastroenterol; 1999 Nov 17; 94(11):3254-7. PubMed ID: 10566725 [Abstract] [Full Text] [Related]
15. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients. Wong DR, Pierik M, Seinen ML, van Bodegraven AA, Gilissen LP, Bus P, Bakker JA, Masclee AA, Neef C, Engels LG, Hooymans PM. J Crohns Colitis; 2014 Feb 17; 8(2):120-8. PubMed ID: 23932783 [Abstract] [Full Text] [Related]
16. Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance. Park MS, Kim DH, Kim DH, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Dig Dis Sci; 2015 Jan 17; 60(1):195-204. PubMed ID: 25239495 [Abstract] [Full Text] [Related]
17. Medical therapy of inflammatory bowel disease for the 21st century. Robinson M. Eur J Surg Suppl; 1998 Jan 17; (582):90-8. PubMed ID: 10029372 [Abstract] [Full Text] [Related]
18. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course. Harris RE, Aloi M, de Ridder L, Croft NM, Koletzko S, Levine A, Turner D, Veereman G, Neyt M, Bigot L, Ruemmele FM, Russell RK, PIBD SETQuality consortium and PIBDnet. BMJ Open; 2020 Jul 01; 10(7):e034892. PubMed ID: 32611737 [Abstract] [Full Text] [Related]
19. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger. Grossman AB, Noble AJ, Mamula P, Baldassano RN. Inflamm Bowel Dis; 2008 Jun 01; 14(6):750-5. PubMed ID: 18266236 [Abstract] [Full Text] [Related]
20. Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease. Morales A, Salguti S, Miao CL, Lewis JD. Inflamm Bowel Dis; 2007 Apr 01; 13(4):380-5. PubMed ID: 17206711 [Abstract] [Full Text] [Related] Page: [Next] [New Search]